Berotralstat (Orladeyo®). HTA ID: 22031

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 22031
Drug Berotralstat
Brand Orladeyo®
Indication Routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older
Assessment Process
Rapid review commissioned 09/05/2022
Rapid review completed 03/06/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of berotralstat compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 28/03/2023